The influence of psychiatric comorbidity on the dexamethasone/CRH test in major depression

Publication Type:

Journal Article

Source:

Eur Neuropsychopharmacol, Volume 19, Number 6, p.409-415 (2009)

DOI Name (links to online publication)

10.1016/j.euroneuro.2009.02.007

Keywords:

Anxiety; AXIS; cortisol; Depression; DISORDER; HPA; MAJOR DEPRESSION; methods; Netherlands; Research; RESPONSES; Somatoform Disorders

Abstract:

BACKGROUND: The outcome of the dexamethasone/corticotropin-releasing-hormone (DEX/CRH) test in depressed patients is heterogeneous. The present study investigated whether comorbidity of anxiety or somatoform disorders might be an explaining factor for this finding. METHODS: The DEX/CRH test was administered in 36 pure major depressive outpatients, 18 major depressive outpatients with a comorbid anxiety and/or somatoform disorder, and 43 healthy controls. Patients were free of psychotropic medication. Group differences in responsivity to the DEX/CRH test were analysed. RESULTS: Depressive patients with comorbidity showed a significant lower cortisol response compared to pure depressive patients (p = 0.04) and controls (p = 0.003). Group differences between MDD patients with and without comorbidity in cortisol responses disappeared after adjustment for post-DEX cortisol concentrations (p = 0.34). CONCLUSIONS: An enhanced suppression of cortisol to 1.5 mg DEX is present in a subgroup of depressed patients with psychiatric comorbidity. Distinct hypothalamic-pituitary-adrenal (HPA) axis dysfunctions are revealed when comorbidity is taken into account

18/01/2013